PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ChromaDex Corporation (CDXC)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US1710774076

CUSIP

171077407

Sector

Healthcare

IPO Date

Jul 15, 2008

Highlights

Market Cap

$448.37M

EPS (TTM)

$0.02

PE Ratio

293.50

Total Revenue (TTM)

$79.81M

Gross Profit (TTM)

$43.39M

EBITDA (TTM)

$1.74M

Year Range

$1.48 - $7.97

Target Price

$7.96

Short %

4.27%

Short Ratio

6.16

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
CDXC vs. SPY
Popular comparisons:
CDXC vs. SPY

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ChromaDex Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%50.00%100.00%SeptemberOctoberNovemberDecember2025February
79.52%
9.03%
CDXC (ChromaDex Corporation)
Benchmark (^GSPC)

Returns By Period

ChromaDex Corporation had a return of 10.65% year-to-date (YTD) and 262.35% in the last 12 months. Over the past 10 years, ChromaDex Corporation had an annualized return of 3.50%, while the S&P 500 had an annualized return of 11.26%, indicating that ChromaDex Corporation did not perform as well as the benchmark.


CDXC

YTD

10.65%

1M

-1.18%

6M

79.51%

1Y

262.35%

5Y*

7.79%

10Y*

3.50%

^GSPC (Benchmark)

YTD

3.96%

1M

1.97%

6M

9.03%

1Y

22.16%

5Y*

12.60%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of CDXC, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20256.13%10.65%
20242.10%14.38%108.38%1.72%-22.03%-1.09%9.52%15.38%5.80%-4.38%121.20%-31.28%270.98%
202316.67%-14.80%-8.38%-13.73%6.82%11.35%9.55%-7.56%-8.18%-9.59%5.30%2.88%-14.88%
2022-24.87%-2.85%-9.89%-23.17%0.53%-12.11%2.99%-16.28%-14.58%23.58%13.16%-2.33%-55.08%
2021-1.25%193.88%-32.95%-4.93%-6.53%18.80%-11.87%-1.84%-26.49%-1.28%-24.23%-20.26%-22.08%
20202.32%-16.33%-11.65%53.37%-3.80%-4.57%10.24%-2.17%-18.99%12.47%9.98%-3.23%11.37%
2019-2.92%4.80%20.06%6.21%-10.56%16.83%-0.43%-15.55%0.64%-26.56%25.95%18.41%25.66%
2018-21.60%18.22%-22.94%-16.43%-3.99%10.09%20.75%1.12%-5.30%-18.88%2.01%-3.38%-41.67%
2017-16.01%-0.72%-2.54%15.61%5.47%16.46%-9.69%-2.61%27.98%-4.88%69.19%-15.03%77.64%
20169.02%0.75%5.97%4.46%17.30%-20.69%-3.38%-17.75%-9.42%-7.38%-11.96%36.21%-9.56%
20158.97%43.75%-5.07%-9.16%-0.17%1.85%-9.50%16.44%-12.94%28.83%-5.59%-9.63%38.48%
201410.53%2.38%6.40%-21.31%5.56%-14.47%3.08%-12.76%-7.61%-7.41%13.90%-22.65%-42.04%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 94, CDXC is among the top 6% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of CDXC is 9494
Overall Rank
The Sharpe Ratio Rank of CDXC is 9696
Sharpe Ratio Rank
The Sortino Ratio Rank of CDXC is 9595
Sortino Ratio Rank
The Omega Ratio Rank of CDXC is 9393
Omega Ratio Rank
The Calmar Ratio Rank of CDXC is 9494
Calmar Ratio Rank
The Martin Ratio Rank of CDXC is 9393
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ChromaDex Corporation (CDXC) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for CDXC, currently valued at 2.57, compared to the broader market-2.000.002.004.002.571.83
The chart of Sortino ratio for CDXC, currently valued at 3.75, compared to the broader market-6.00-4.00-2.000.002.004.006.003.752.47
The chart of Omega ratio for CDXC, currently valued at 1.45, compared to the broader market0.501.001.502.001.451.33
The chart of Calmar ratio for CDXC, currently valued at 2.90, compared to the broader market0.002.004.006.002.902.76
The chart of Martin ratio for CDXC, currently valued at 11.63, compared to the broader market-10.000.0010.0020.0030.0011.6311.27
CDXC
^GSPC

The current ChromaDex Corporation Sharpe ratio is 2.57. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ChromaDex Corporation with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio1.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
2.57
1.83
CDXC (ChromaDex Corporation)
Benchmark (^GSPC)

Dividends

Dividend History


ChromaDex Corporation doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-68.68%
-0.07%
CDXC (ChromaDex Corporation)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ChromaDex Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ChromaDex Corporation was 97.00%, occurring on Aug 3, 2009. Recovery took 2854 trading sessions.

The current ChromaDex Corporation drawdown is 68.68%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97%Sep 23, 200896Aug 3, 20092854Feb 25, 20212950
-93.65%Feb 26, 2021399Sep 26, 2022
-25%Jul 16, 20081Jul 16, 20081Jul 17, 20082
-22.22%Jul 29, 20083Aug 18, 20081Aug 19, 20084

Volatility

Volatility Chart

The current ChromaDex Corporation volatility is 11.76%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
11.76%
3.21%
CDXC (ChromaDex Corporation)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ChromaDex Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an assessment of the market value of ChromaDex Corporation compared to its peers in the Biotechnology industry.


PE Ratio
100.0200.0300.0400.0500.0600.0293.5
The chart displays the price to earnings (P/E) ratio for CDXC in comparison to other companies of the Biotechnology industry. Currently, CDXC has a PE value of 293.5. This PE ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.
PEG Ratio
-1,000.0-800.0-600.0-400.0-200.00.00.0
The chart displays the price to earnings to growth (PEG) ratio for CDXC in comparison to other companies of the Biotechnology industry. Currently, CDXC has a PEG value of 0.0. This PEG ratio is much higher than those of other companies of the industry. This might be an indicator of the company being overvalued.

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for ChromaDex Corporation.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab